{"name":"Atox Bio Ltd","slug":"atox-bio-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AB103","genericName":"AB103","slug":"ab103","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"AB103","genericName":"AB103","slug":"ab103","phase":"phase_2","mechanism":"AB103 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNV1dRSUg1LVpTcElDcnVWQzI0RmpRRFpvdnVMZ3ZwVm9ObFJvazVCaGxpVTFpLUlJQXdEenA3MWVuNUhSSUNkcmxBeVBHQ0VvdC05b2V3SC1SVElVMmlJODM3NWVUOE85Z1dxel8zblctLW83NkVnNUd0aG5HUkVLdGNfLTZhMW1aX2JLdjFRbDNjZVhrUEE?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Leading Companies Spearheading Innovation and Growth in the Acute Pancreatitis Market - openPR.com","headline":"Leading Companies Spearheading Innovation and Growth in the Acute Pancreatitis Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxOeFNuemo4SG1Oa0g1Y3h1UENlUzY5Y0RRdkdNdHhhclN4UHdBQW9xMmgxd0Fya19FRktyUG5BQ2hVQ1RxemJ4TGc5eWZJejJ0cEhUNHp3NXRhc3poRWVaRWs4S0E5QzlhNUVncjZIWDdWZENqc0QzTXkxenlaWlZIWTZjYnphZTdfd3FXZ3JfNTZlNmJzQ2xzQllrYm16aXV6c3BRMFk5Vmx1RUt0MFlYb1ZsSlZTOEVJcV82RlFBUWdmSDM0Q3NXWktyWWg4RkhSMmtMTUhpOWRpeUhCZDRlTHlVQXBtQVBZNTI0V01ncTJjX2ppdHFWYlN1UXJzZ0NTNUlSclZUckZyb1oyRTc1OHUyVXpjNno3VWlSQVY1eWNsSU9CQjZvdzl4c3pBNGR4WkFKbXZhNGFQUS1qbE5McEptV1N3OTJoSjhn?oc=5","date":"2020-12-10","type":"regulatory","source":"BioSpace","summary":"Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (\"Flesh-Eating Disease\") - BioSpace","headline":"Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Pati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNM1ZaSDFoRTNDTWRsaWhYdzFzbm9aTWRxdXJJckh3OWdYNlF0N0tRU3V2MHRJTmR3TzltS3hwWXJ4VUxWZTdvY2xXV3hnY1ZDWHpLNHJURFVLOU43VXUtbnVXZGR3eG95NG5NTWgyeHlvaEtKelRpaGJKZFA0Y2haWTBHcUdhU21GWS1NU1k1YVVFb21BYjNZTmVFeFBTbkhoeXdZbElyandSMG1fQnZMUThMRzhyaWtCekZkckNka2o?oc=5","date":"2018-01-10","type":"pipeline","source":"The Jerusalem Post","summary":"Israeli drug could successfully treat flesh-eating bacteria - The Jerusalem Post","headline":"Israeli drug could successfully treat flesh-eating bacteria","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}